| scholarly article | Q13442814 |
| P50 | author | Alexander C. Ford | Q37829208 |
| P2093 | author name string | C F Donnellan | |
| P J Hamlin | |||
| L Warren | |||
| S M Everett | |||
| N C Suares | |||
| D Greer | |||
| M B Sprakes | |||
| J S R Jennings | |||
| P2860 | cites work | Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology | Q40390478 |
| P433 | issue | 11-12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Crohn's disease | Q1472 |
| P304 | page(s) | 1357-1363 | |
| P577 | publication date | 2010-10-07 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience | |
| P478 | volume | 32 |
| Q38608989 | A UK cost of care model for inflammatory bowel disease |
| Q43671238 | A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease |
| Q38116341 | A systematic review of economic studies on biological agents used to treat Crohn's disease |
| Q38630959 | Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. |
| Q36136475 | Burden of Crohn's disease: economics and quality of life aspects in Italy. |
| Q45181725 | Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. |
| Q44332424 | Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study |
| Q38488635 | Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation |
| Q38845478 | Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. |
| Q52844170 | Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. |
| Q38086355 | First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? |
| Q35452992 | Health care resource use and costs in Crohn's disease before and after infliximab therapy |
| Q38067127 | Infliximab for the treatment of pediatric ulcerative colitis |
| Q38122070 | Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis |
| Q92030207 | Long-term implications of structured transition of adolescents with inflammatory bowel disease into adult health care: a retrospective study |
| Q39818677 | Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective |
| Q91789213 | The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization |
| Q38241338 | The cost-effectiveness of infliximab in Crohn's disease |
| Q27030762 | Use of the tumor necrosis factor-blockers for Crohn's disease |
| Q45329381 | WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease |
Search more.